Or if you're already a Pharma IQ member, sign in below to download. Sign In Join
In 2008 and 2009, Genzyme sites were affected by vesivirus infection. This shut down two sites for decontamination. In this candid interview, Lada Laenen, Managing Principal Scientist, Head, Cell Culture and Microbiology, Genzyme, a Sanofi Company, discusses how this affected Genzyme. She explains what they have changed to avoid this happening again. Dr. Laenen also describes the company's creation of an 'organisms of concern' list, ensuring quality in raw materials and what's holding back the use of new technologies for pathogen detection.